Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BASF & vitamin C

This article was originally published in The Tan Sheet

Executive Summary

Company to shut down crystalline vitamin C line at Wilmington, N.C. facility by July 2002 but will continue to run vitamin C granulating, packaging operations at the site, ingredient supplier says Nov. 15. Move is aimed at strengthening BASF's market position by concentrating vitamin C manufacturing efforts "on areas that deliver better cost competitiveness and economies of scale," company says. BASF acquired the Wilmington site in January through its purchase of Takeda Chemical Industries' bulk vitamin business (1"The Tan Sheet" Aug. 7, 2000, p. 9)...

You may also be interested in...



BASF Global Vitamin Presence Strengthened With Takeda Combination

BASF's agreement to combine its bulk vitamins business with that of Takeda Chemical Industries considerably strengthens the chemical giant's position in the global vitamins market.

Executives On The Move: Eisai Taps Celgene And Sanofi VPs For Its Team, And Freeline Selects A CEO

Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.

Triptan Switches Offer Hope For Australia’s OTC Market

Switch expert Natalie Gauld says recent triptan switch recommendations signal a turnaround for Australia's OTC market.

Topics

UsernamePublicRestriction

Register

PS093273

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel